Buspirone for autistic disorder in a woman with an intellectual disability

Annals of Pharmacotherapy

Volumn 42, Issue 1, 2008, Pages 131-137

  Brahm, Nancy C ^a   Fast, Gary A ^b   Brown, Robert C ^a,c,d  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b Outpatient Psychiatry   (United States)

^c Oklahoma Department of Human Services/DDSD

^d Oklahoma City   (United States)

Author keywords

Autism; Buspirone; Developmentally disabled; Intellectual disability

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; BUSPIRONE; CLONAZEPAM; CLOZAPINE; ETHINYLESTRADIOL PLUS NORETHISTERONE; MULTIVITAMIN; NALTREXONE; PHENYTOIN; PROLACTIN; RISPERIDONE; SERTRALINE; VALPROATE SEMISODIUM;

ADULT; AGGRESSION; ARTICLE; AUTISM; AUTOMUTILATION; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERPROLACTINEMIA; INTELLECTUAL IMPAIRMENT; OSTEOPOROSIS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SEIZURE; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGGRESSION; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; BUSPIRONE; EPILEPSY; FEMALE; HUMANS; HYPERPROLACTINEMIA; MENTAL RETARDATION; OSTEOPOROSIS; SELF-INJURIOUS BEHAVIOR; TREATMENT OUTCOME;

EID: 38049051727     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K427     Document Type: Article

References (23)

1. Diagnostic and statistical manual of mental disorders, 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000.
2. Rice C. Prevalence of autism spectrum disorders - autism and developmental disabilities monitoring network, six sites, United States, 2000. MMWR Surveill Summ 2007;56:1-11.
3. Stachnik JM, Nunn-Thompson C. Use of atypical antipsychotics in the treatment of autistic disorder. Ann Pharmacother 2007;41:626-34. Epub 27 Mar 2007. DOI 10.1345/aph.1H527
4. Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E. Divalproex sodium vs placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol 2006;9:209-13.
5. King BH, Bostic JQ. An update on pharmacologic treatments for autism spectrum disorders. Child Adolesc Psychiatr Clin North Am 2006;15:161-75.
6. Package insert. BuSpar (buspirone). Princeton, NJ: Bristol-Myers Squibb Co., March 2007.
7. Package insert. Risperdal (risperidone). Titusville, NJ: Janssen, L.P., August 2007.
8. Minshew NJ, Williams DL. The new neurobiology of autism: cortex, connectivity, and neuronal organization. Arch Neurol 2007;64:945-50.
9. Schlosser R, Gesierich T, Kaufmann B, et al. Altered effective connectivity during working memory performance in schizophrenia: a study with fMRI and structural equation modeling. Neuroimage 2003;19:751-63.
10. Hunsinger DM, Nguyen T, Zebraski SE, Raffa RB. Is there a basis for novel pharmacotherapy of autism? Life Sci 2000;67:1667-82.
11. Posey DJ, McDougle CJ. The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv Rev Psychiatry 2000;8:45-63.
12. McCormick LH. Treatment with buspirone in a patient with autism. Arch Fam Med 1997;6:368-70.
13. Anderson GM, Scahill L, McCracken JT, et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 2007;61:545-50.
14. Volavka J, Czobor P, Cooper TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 2004;65:57-61.
15. Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007;164:1404-10.
16. Hedges D, Jeppson K, Whitehead P. Antipsychotic medication and seizures: a review. Drugs Today (Barc) 2003;39:551-7.
17. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:843-53.
18. Wong J, Delva N. Clozapine-induced seizures: recognition and treatment. Can J Psychiatry 2007;52:457-63.
19. Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007;167:1240-5.
20. Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother 2006;40:1618-22. Epub 8 Aug 2006. DOI 10.1345/aph.1G293
21. Elchaar GM, Maisch NM, Augusto LM, Wehring HJ. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Ann Pharmacother 2006;40:1086-95. Epub 30 May 2006. DOI 10.1345/1aph.1G499
22. McDougle CJ, Brodkin ES, Naylor ST, Carlson DC, Cohen DJ, Price LH. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol 1998;18:62-6.
23. Kolevzon A, Mathewson KA, Hollander E. Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability. J Clin Psychiatry 2006;67:407-14.